BMS injects $100 million in new drug development, IT & digital innovation hub in Hyderbad

Biopharma giant Bristol Myers Squibb (BMS) has invested $100 million in a new cutting edge facility in Hyderabad that will expand the company’s global drug development and IT & digital capabilities.
The new facility, which will expand BMS’s global footprint and will serve as an innovation hub, is expected to house over 1,500 employees.
“Our $100 million investment in Hyderabad will bring over 1,500 BMS employees together across IT and drug development to enhance our innovation capabilities for patients everywhere,” BMS said.
BMS CEO Christopher Boerner said the new innovation hub in Hyderabad will accelerate drug development and enhance the company’s digital capabilities.
“This investment also enables us to further diversify our global workforce by adding world-class local talent and strengthening our ability to positively impact patients everywhere,” said Boerner who opened the facility along with Telangana industries and IT minister D Sridhar Babu.
Sridhar Babu said the opening of BMS’s new facility marks an important milestone and investment, offering opportunities for Telangana’s rich talent pool to work at the forefront of science and innovation.
“I am proud of this strategic partnership with BMS, which brings new R&D and IT capabilities to Telangana. We have a wealth of remarkable talent in Telangana that will be able to contribute to important and impactful work at BMS,” he added.
BMS, which has had a presence in India for over 25 years, sees the latest investment a highlighting the importance of India’s role in its global business.
In Bangalore, in partnership with Syngene International, BMS employees in R&D work on supporting target identification, lead discovery and optimisation, among others, while in Mumbai, it has been providing medicines to support cancer patients for over a decade.
Source: TimesOfIndia